Product pipeline

ISA Pharmaceuticals develops novel therapeutic vaccines for cancer and infectious diseases by leveraging its proprietary SLP® technology to achieve therapeutic efficacy.

ISA's lead product is a therapeutic HPV vaccine against Vulvar Intraepithelial Neoplasia(VIN) with Cervical Intraepithelial Neoplasia (CIN), and cervical carcinoma as first follow up indications. The company's pipeline further contains vaccines in development against ovarian cancer, colorectal cancer, melanoma and tuberculosis as well as immunomodulating agents such as Adjuvant IS, Toll-like Receptor Based Adjuvants and CD40 agonist.

Impressive clinical results with the HPV vaccine have encouraged ISA to apply its proprietary SLP® technology in a broad range of other indications in cancer and infectious diseases. In parallel the company is active in various adjuvants programs to even further improve the efficacy of its SLP®-vaccines.

For early-stage clinical trials ISA collaborates with leading medical centers in Europe and the US. Through its collaboration with LUMC's GMP-facility for small batch clinical grade peptide production, ISA is in a position to perform those clinical trials in a flexible and cost-effectively manner.